Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada

Health Policy

Volumn 87, Issue 3, 2008, Pages 359-368

  Rosenberg Yunger, Zahava R S ^a   Daar, Abdallah S ^b   Singer, Peter A ^b   Martin, Douglas K ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c University of Toronto   (Canada)

Author keywords

Biotechnology; Fairness; Priority setting; Resource allocation

Indexed keywords

ARTICLE; BIOTECHNOLOGY; CANADA; DRUG INDUSTRY; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM;

BIOTECHNOLOGY; CANADA; DIFFUSION OF INNOVATION; DRUG DESIGN; GOVERNMENT AGENCIES; HEALTH PLANNING COUNCILS; HEALTH POLICY; HEALTH PRIORITIES; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; ORPHAN DRUG PRODUCTION; REGIONAL HEALTH PLANNING; RESOURCE ALLOCATION; SOCIAL JUSTICE;

EID: 47849099279     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.02.004     Document Type: Article

References (59)

1. Society for Mucopolysaccharide Diseases [cited June 8, 2006]; available from: http://www.mpssociety.co.uk/pages/maroteaux.htm.
2. Priest L. A Family's Choice to Relocate or Watch their Toddler Suffer, April 29; 2006 [cited May 10, 2006]; available from: www.globeandmail.com.
3. Naglazyme [cited June 11, 2006]; available from: http://www.naglazyme.com/.
4. Priest L. Boy to get costly drug [cited August 15, 2006]; available from: http://www.theglobeandmail.com/servlet/ArticleNews/freeheadlines/LAC/20060715/BOY15/health/Health.
5. Isaac Foundation [cited November 15, 2007]; available from: www.theisaacfoundation.com/isaac.doc.
6. Clarke J.T.R. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 174 2 (2006)
7. Fernandez C.V. Our moral obligations in caring for patients with orphan cancers. CMAJ 176 3 (2007)
8. A framework for biotechnology statistics. OECD; 2005 [cited July 18, 2006]; available from: http://www.oecd.org/dataoecd/5/48/34935605.pdf.
9. Innovation in Pharmaceutical Biotechnology: Comparing International Systems at the Sectoral Level, OECD, Editor; 2006.
10. Pisano G.P. Science business (2006), Boston Harvard Business School Press
11. Drug expenditure in Canada 1985-2006; 2006. Accessed on November 8, 2007 from Canadian Institute for Health Information 2006 [cited November 8, 2007]; available from: www.secure.cihi.ca-Drug_Expenditure_in_Canada_2007_e.pdf.
12. Projecting OECD health and long-term care expenditures: what are the main drivers? Economics Department Working Papers No. 477 2006 [cited July 24, 2006]; available from: http://www.oecd.org/dataoecd/57/7/36085940.pdf.
13. Deber R. Translating technology assessment into policy: conceptual issues and tough choices. International Journal of Technology Assessment in Health Care 8 1 (1992) 131-137
14. Romanow RJ. Shape of the Future of Health Care Interim Report, G.o. Canada, Editor; 2002. p. 1.
15. Innovation in the pharmaceutical sector: a study undertaken for the European commission. 2004 [cited November 12, 2007]; available from: ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2004/nov/eu_pharma_innovation_25-11-04.pdf.
16. A Vision for a Healthier Tomorrow. Financial Post Business Joint Venture Supplement; May 2007. p. 1-8.
17. OECD [cited July 27, 2006]; available from: http://www.oecd.org/document/0,2340,en_2649_34487_25998799_1_1_1_1,00.html.
18. Thorsteinsdóttir H. The Role of the Health System in Health Biotechnology in Developing Countries. Technology Analysis & Strategic Management 19 5 (2007) 659-675
19. Luger M, Maynard N, Christie L. European Trend Chart on Innovation. Annual Innovation Policy Trends Report for United States, Canada, Mexico and Brazil. E.C.E. Directorate-General, Editor; 2005.
20. CIHR [cited October 26, 2006]; available from: http://www.cihr-irsc.gc.ca/e/30240.html#slide1_e.
21. Industry Canada. Achieving excellence: investing in people, knowledge and opportunity Canada's innovation strategy 2001 [cited 2006 February 7]; Available from: http://www.innovationstrategy.gc.ca/gol/innovation/site.nsf/vDownload/Page_PDF/$file/Achieving.pdf.
22. Innovation in Canada. Submission - Federal Department Report - Innovation and Health [cited February 21, 2006]; available from: http://www.innovationstrategy.gc.ca/gol/innovation/site.nsf/en/in02330.htm.
23. Economic Importance of Biotechnology Industry to Canada. Accessed on February 7, 2006 from [cited February 7, 2006]; available from: http://www.biotech.ca/EN/baMay0801.html.
24. OECD Science, Technology and Industry Outlook 2004 Country Response to Policy Questionnaire [cited February 7, 2006]; available from: www.oecd.org/document/60/0,2340,en_2649_33703_33995839_1_1_1_1,00.html.
25. Industry Canada [cited February 7, 2006]; available from: http://www.biostrategy.gc.ca/english/View.asp?pmiid=520&x=535.
26. Niosi J., and Tomas B.G. Canadian biotech policy: designing incentive for new technology. Environment and Planning Government and Policy 22 (2004) 233-248
27. Canada's Biotechnology Strategy [cited May 10, 2007]; available from: http://hc-sc.gc/sr-sr/biotech/role/strateg/index_e.html.
28. Canadian Biotechnology Advisory Committee [cited May 10, 2007]; available from: http://www.cbac-cccb.ca/epic/site/cbac-cccb.nsf/en/h_ah00002e.html.
29. Canadian Biotechnology Strategy [cited February 7, 2006]; available from: http://www.tbs-sct.gc.ca/rma/eppi-ibdrp/hrdb-rhbd/cbs-scb/description_e.asp#g3.
30. Backing Australia's ability [cited July 18, 2006]; available from: http://backingaus.innovation.gov.au/info_booklet/exec_summary.htm.
31. Competing in the global economy: the innovation challenge D.I. Report, Editor; 2003.
32. Martin R, Milway J. Assessing the Strength of the Toronto Biopharmaceutical Cluster. 2004 [cited January 31, 2007]; available from: http://www.competeprosper.ca/clusters/biopharmaCluster.pdf.
33. Romanow RJ. Building on Values: The Future of Health Care in Canada T.C.o.t.f.o.h.i. Canada, Editor; 2002, Government of Canada.
34. Zelmer J, et al. Health Care in Canada 2007, C.I.f.H. Information, Editor. Ottawa: Canadian Institute for Health Information; 2007.
35. Danzon P.M., and Furukawa M. Prices and availability of biopharmaceuticals: an internal comparison. Health Affairs 25 (2006) 1353-1362
36. Lorinc J. How much are drugs worth? University of Toronto Magazine. Toronto; 2006. p. 28-29.
37. Drug Expenditure in Canada 1985-2003, CIHI, Editor. Ottawa: Canadian Institute for Health Information; 2004. p. 91-93.
38. Sykes RB. New Medicines: The Practice of Medicine and Public Policy. London: Stationery Office; 2000.
39. Common Drug Review Process [cited October 11, 2007]; available from: http://www.cadth.ca/index.php/en/cdr/process.
40. CEDAC [cited November 17, 2007]; available from: http://www.cadth.ca/index.php/en/cdr/committees/cedac.
41. CEDAC. CDR drug database listing on agalsidase beta; 2005 [cited November 17, 2007]; available from: http://www.cadth.ca/index.php/en/cdr/search/?&status=all&keywords=agalsidase%20beta.
42. Koning E. Patient's Perspective on Access to Innovative Therapies for Rare Disorders [cited November 27, 2007]; available from: http://www.cord.ca/index.php/site/content/search?SearchText=koning.
43. Special Access Programme; 2005 [cited November 15, 2007]; available from: http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/sapfs_pasfd_2002_e.html.
44. Drug Product Search; 2007 [cited November 15, 2007]; available from: http://cpe0013211b4c6d-cm0014e88ee7a4.cpe.net.cable.rogers.com/dpdonline/startup.do.
45. Biotechnology, Innovation, and Health [cited December 5, 2005]; available from: http://www.oecd.org/document/10/0,2340,en_2649_201185_33790794_1_1_1_1,00.html.
46. Toward a Canadian Action Agenda for Biotechnology, C.B.A. Committee, Editor; 2006. p. 57.
47. In: Coulter A., and Ham C. (Eds). The global challenge of health care rationing: state of health (2000), Open University Press, Buckingham
48. PausJenssen A., Singer P.A., and Detsky A.S. How Ontario's formulary committee makes recommendations. Pharmacoeconomics 21 (2003) 285-294
49. Clarke J.T.R., Amato D., and Deber R.B. Managing public payment for high cost, high-benefit therapy for Gaucher's disease in Ontario. CMAJ 165 5 (2001) 595
50. Wiktorowicz M., and Deber R. Regulating biotechnology: a rational-political model of policy development. Health Policy 40 (1997) 116
51. Daniels N., and Sabin J. Setting limits fairly (2002), Oxford University Press, Oxford p. 191
52. Murphy-Berman V., Cross T., and Fondacaro M. Fairness, health care decision making: testing the group value model of procedural justice. Social Justice Research 12 2 (1999) 117-129
53. Fondacaro M., Frogner B., and Moos R. Justice in health care decision-making: patients' appraisals of health care providers and health plan representatives. Social Justice Research 18 1 (2005) 65
54. Committee to Evaluate Drugs [cited November 29, 2007]; available from: http://www.health.gov.on.ca/english/providers/program/drugs/ced_recommend.html#2.
55. Joncheere Kd, et al. The Clinical Guideline Programme of the National Institute for Health and Clinical Excellence (NICE) A review by the World Health Organization, W.H. Organization, Editor. Denmark: World Health Organization; 2006, p. 12.
56. NICE Special Health Authority The Clinical Guideline Programme A Review by the WHO Response to Recommendations 2007 [cited November 18, 2007]; available from: http://www.nice.org.uk/niceMedia/pdf/boardmeeting/brdjan07item2c.pdf.
57. Mitton C., et al. Centralized drug review processes: are they fair?. Social Science and Medicine 63 1 (2006) 200-211
58. Cohen S.S. The drive toward transparency: enhancing openness and accountability. Healthcare Executive 20 4 (2005) 16
59. Anderson K., et al. Models of transparency and accountability in the biotech age. Bulletin of Science Technology and Society 26 1 (2006) 46-56